Pharvaris (NASDAQ:PHVS) Issues Earnings Results

Pharvaris (NASDAQ:PHVS) released its earnings results on Wednesday. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.05), FiscalAI reports.

Pharvaris Price Performance

Shares of Pharvaris stock traded up $0.22 during trading on Wednesday, reaching $34.64. 575,409 shares of the stock traded hands, compared to its average volume of 305,670. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -10.89 and a beta of -2.31. The business has a fifty day simple moving average of $33.46 and a two-hundred day simple moving average of $29.95. Pharvaris has a 52-week low of $20.65 and a 52-week high of $36.60.

Insider Transactions at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 27,872 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.48, for a total transaction of $988,898.56. Following the completion of the transaction, the insider owned 58,750 shares in the company, valued at $2,084,450. This trade represents a 32.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the sale, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 178,322 shares of company stock valued at $5,969,286.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System raised its position in Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after purchasing an additional 520 shares during the period. JPMorgan Chase & Co. grew its position in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after acquiring an additional 1,300 shares during the last quarter. Legal & General Group Plc increased its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the period. Finally, Swiss National Bank lifted its position in shares of Pharvaris by 5.7% during the fourth quarter. Swiss National Bank now owns 44,757 shares of the company’s stock worth $1,242,000 after purchasing an additional 2,400 shares during the last quarter.

Wall Street Analysts Forecast Growth

PHVS has been the subject of a number of analyst reports. Citigroup reissued a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. UBS Group set a $74.00 price target on Pharvaris in a research note on Wednesday, May 13th. Finally, Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $50.08.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.